DPYD rs56038477: Understanding the HapB3 Variant
The rs56038477 variant in the DPYD gene, often referred to as part of the HapB3 haplotype, is a genetic change associated with the body's ability to process fluoropyrimidine chemotherapy drugs. Research suggests that individuals carrying this variant may have an altered risk of experiencing severe side effects from these medications.
What each genotype means
Normal enzyme activity
This genotype is considered the common or wild-type form for this specific variant. Individuals with this profile are not expected to have the reduced enzyme activity associated with the HapB3 haplotype. Please consult with your oncologist or pharmacist regarding standard dosing protocols for fluoropyrimidine medications.
This is the most common genotype, found in the vast majority of the population.
Reduced enzyme activity
This genotype indicates you carry one copy of the HapB3 haplotype, which is associated with a moderate reduction in dihydropyrimidine dehydrogenase (DPD) enzyme activity. Research suggests this may increase the risk of experiencing toxicity when treated with fluoropyrimidine-based chemotherapy. You should discuss this result with your healthcare provider, as they may consider dose adjustments to ensure your treatment is safe.
This genotype is carried by approximately 4% to 5% of individuals of European ancestry.
Significantly reduced enzyme activity
This genotype indicates you carry two copies of the HapB3 haplotype, which is associated with a more pronounced reduction in DPD enzyme activity compared to carrying a single copy. This may further increase the risk of severe side effects from fluoropyrimidine medications. It is essential to discuss this finding with your clinical team before starting any chemotherapy, as they will need to determine the appropriate management or alternative treatment strategy.
This genotype is rare in the general population.
What is rs56038477?
The rs56038477 variant is a specific genetic change located within the DPYD gene. In scientific literature, it is frequently identified as a deep intronic variant, specifically c.1129-5923C>G, and is a key component of what researchers call the HapB3 haplotype. Because it is located in an intron—a non-coding region of the gene—it does not change the protein sequence directly. Instead, it is thought to influence how the gene is spliced, which can affect the production of the DPD enzyme. Geneticists study this variant because it serves as a marker for potential differences in how patients metabolize certain drugs. It is important to note that while this variant is studied in the context of pharmacogenomics, its specific functional impact is still a subject of ongoing research, and it is often analyzed alongside other DPYD variants to get a clearer picture of a patient's metabolic profile.
The Role of the DPYD Gene
The DPYD gene provides instructions for making an enzyme called dihydropyrimidine dehydrogenase (DPD). This enzyme is essential for the breakdown of uracil and thymine, which are normal building blocks of DNA and RNA. Crucially, the DPD enzyme is also responsible for breaking down fluoropyrimidines, a class of chemotherapy drugs that includes 5-fluorouracil (5-FU) and capecitabine. When the DPD enzyme functions normally, these drugs are cleared from the body at a predictable rate. However, if the DPD enzyme is deficient or inactive, these drugs can accumulate to toxic levels in the bloodstream. This accumulation can lead to severe, and sometimes life-threatening, side effects, including gastrointestinal distress, bone marrow suppression, and neurotoxicity. Understanding DPYD variants helps clinicians identify patients who might require dose adjustments to ensure treatment remains safe and effective.
Research and Evidence Strength
The association between rs56038477 (HapB3) and fluoropyrimidine toxicity is considered to have limited or mixed evidence compared to other well-established DPYD variants like DPYD*2A. While some studies have identified this variant in patients who experienced severe toxicity, other research has suggested that its predictive value for severe adverse events may be lower than that of other known loss-of-function variants. Because of this, the clinical interpretation of HapB3 can be complex. Some international guidelines include it in screening panels, while others emphasize that it may not be as strong a predictor of toxicity as other genetic markers. Current research continues to evaluate how much this specific variant contributes to the overall risk profile of a patient. Because the evidence is not as definitive as for other variants, clinicians often weigh this information carefully alongside a patient's full clinical history and other genetic factors.
Population Frequency
The rs56038477 variant is found in various populations, with a minor allele frequency typically reported between 2% and 3% in individuals of European ancestry. Because it is relatively uncommon, most people do not carry this specific genetic change. Frequency can vary significantly across different global populations, which is a common theme in pharmacogenomics. Understanding the prevalence of this variant in a specific population helps researchers design better studies and helps healthcare providers understand the likelihood of encountering this variant in their patient base. It is important to remember that population frequency is a statistical observation and does not predict an individual's personal risk. Genetic testing is the only way to determine an individual's specific genotype for this variant.
What You Can Do With This Information
If you have received information about your DPYD genotype, it is essential to discuss these results with your oncologist, pharmacist, or a genetic counselor. This information is intended for educational purposes and should never be used to make personal medical decisions, such as stopping or changing a prescribed medication. If you are scheduled to receive fluoropyrimidine-based chemotherapy, your healthcare team may already have a protocol for DPYD testing. If you have concerns about your risk of toxicity, ask your doctor if pharmacogenetic testing is appropriate for your specific treatment plan. They are the only ones who can interpret your genetic results in the context of your overall health, the specific drug being used, and the intended dosage. Always follow the guidance of your medical team, as they are responsible for managing your treatment safely and effectively.
How common is this variant?
The rs56038477 variant has a minor allele frequency of approximately 0.02 to 0.03 in European ancestry populations.
Frequently asked questions
Is rs56038477 the same as DPYD*2A?
No, rs56038477 and DPYD*2A are different genetic variants. DPYD*2A is a well-known, high-impact variant, while rs56038477 is a deep intronic variant associated with the HapB3 haplotype.
Does having the rs56038477 variant mean I will have chemotherapy toxicity?
Not necessarily. While this variant is associated with an increased risk of toxicity, it is not a guarantee. Many factors, including dosage, other medications, and overall health, influence how a patient responds to chemotherapy.
Should I get tested for DPYD variants before starting chemotherapy?
You should discuss this with your oncologist. Many clinical guidelines recommend testing for certain DPYD variants before starting fluoropyrimidine treatment to help guide dosing and improve safety.
Where can I find more information about DPYD and drug safety?
Resources like PharmGKB and MedlinePlus Genetics provide detailed information on pharmacogenomics. You can also ask your pharmacist or a genetic counselor for information specific to your medications.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs56038477?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in DPYD
This intronic variant is a marker for reduced DPYD enzyme activity, increasing the risk of severe toxicity from fluoropyrimidine-based chemotherapies.
This variant is linked to decreased dihydropyrimidine dehydrogenase activity, increasing the risk of severe toxicity during fluoropyrimidine chemotherapy.
Defines the DPYD*7 variant (p.Leu311Phe) associated with impaired pyrimidine metabolism and potential fluoropyrimidine toxicity.
Constitutes the DPYD*13 variant (p.Ile560Thr), associated with significantly reduced DPYD enzyme activity and increased risk of severe fluoropyrimidine toxicity.
Also designated as DPYD c.557A>G (p.Tyr186Cys), this variant significantly decreases dihydropyrimidine dehydrogenase activity and predisposes patients to severe fluoropyrimidine toxicity.
Causes the c.2846A>T (p.Asp949Val) missense change in DPYD, associated with reduced enzyme activity and increased risk of fluoropyrimidine-associated toxicity.